Conférences
le (1h16m11s)
Résultats de recherche
Trier par :
Nombre de programmes trouvés : 21
Documentaires
le (54m28s)
Aux frontières de la science - Les pouvoirs de l'esprit - Nimbus n°28
... avec le professeur Rhine. Il est apparu alors que certaines personnes semblent douées de perception extrasensorielle : clairvoyance, prémonition ou encore télépathie... De même, par simple effet de conviction, un placebo peut soigner de véritables... Voir la vidéo
Label UNT Conférences
le (57m35s)
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : SHIfTing evidence in heart failure management.
... blockade, who were randomized to add either placebo or ivabradine (pure HR slowing drug) during a median 22.9 months follow-up. The results of SHIFT unambiguously demonstrated the benefits of HR slowing (placebo-subtracted ivabradinemediated HR reduction... Voir la vidéo
Label UNT Conférences
le (26m40s)
Cardiovascular Clinical Trialists (CVCT) Forum – Lipid lowering agents. Now, we have an option! (SHARP, 4D, AURORA)
... BEACON trial assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease and cardiovascular deaths in patients with Stage 4 CKD and type 2 diabetes.- More specifically in chronic hemodialysis... Voir la vidéo
Label UNT Conférences
le (20m6s)
Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients.
... that such agents may have therapeutic benefit in chronic renal failure.- The ongoing BEACON trial assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease and cardiovascular deaths in patients... Voir la vidéo
Label UNT Conférences
le (10m18s)
Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients
... that such agents may have therapeutic benefit in chronic renal failure.- The ongoing BEACON trial assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease and cardiovascular deaths in patients... Voir la vidéo
Label UNT Conférences
le (9m25s)
Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients (debates).
... that such agents may have therapeutic benefit in chronic renal failure.- The ongoing BEACON trial assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease and cardiovascular deaths in patients... Voir la vidéo
Label UNT Conférences
le (22m32s)
Cardiovascular Clinical Trialists (CVCT) Forum – RAAS inhibitors and Mineralocorticoid receptor antagonists (FOSIDIAL, ALCHEMIST)
... chronic renal failure.- The ongoing BEACON trial assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease and cardiovascular deaths in patients with Stage 4 CKD and type 2 diabetes.- More... Voir la vidéo
Label UNT Conférences
le (14m11s)
Cardiovascular Clinical Trialists (CVCT) Forum – Interpretation and approvability issues.
... bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease and cardiovascular deaths in patients with Stage 4 CKD and type 2 diabetes.- More specifically in chronic hemodialysis patients, results from the very few clinical trials... Voir la vidéo
Conférences
le (59m21s)
